Published in Alcohol Res Health on January 01, 2010
Mechanisms of alcohol-mediated hepatotoxicity in human-immunodeficiency-virus-infected patients. World J Gastroenterol (2011) 1.02
Drinking motives among HIV primary care patients. AIDS Behav (2014) 0.97
Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV. AIDS Res Treat (2012) 0.94
Interventions to reduce alcohol use among HIV-infected individuals: a review and critique of the literature. Curr HIV/AIDS Rep (2013) 0.92
Drinking motives as prospective predictors of outcome in an intervention trial with heavily drinking HIV patients. Drug Alcohol Depend (2013) 0.91
Perceived medical risks of drinking, alcohol consumption, and hepatitis C status among heavily drinking HIV primary care patients. Alcohol Clin Exp Res (2014) 0.85
Improving adherence to ante-retroviral treatment for people with harmful alcohol use in Kariobangi, Kenya through participatory research and action. BMC Public Health (2012) 0.84
Reasons for limiting drinking in an HIV primary care sample. Alcohol Clin Exp Res (2014) 0.83
Alcohol use and its association with HIV risk behaviors among a cohort of patients attending HIV clinical care in Tanzania, Kenya, and Namibia. AIDS Care (2014) 0.83
Effects of combined alcohol and anti-HIV drugs on cellular stress responses in primary hepatocytes and hepatic stellate and kupffer cells. Alcohol Clin Exp Res (2015) 0.79
Continued Substance Use Among People Living With HIV-Hepatitis-C Co-Infection and Receiving Antiretroviral Therapy. Subst Use Misuse (2015) 0.75
Reasons for drinking as predictors of alcohol involvement one year later among HIV-infected individuals with and without hepatitis C. Ann Med (2016) 0.75
HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users. AIDS Behav (2016) 0.75
Elevated Linoleic Acid (A Pro-Inflammatory PUFA) and Liver Injury in a Treatment Naive HIV-HCV Co-Infected Alcohol Dependent Patient. J Biosci Med (Irvine) (2016) 0.75
Perceived risk for severe outcomes and drinking status among drug users with HIV and Hepatitis C Virus (HCV). Addict Behav (2016) 0.75
Perceived health and alcohol use in individuals with HIV and Hepatitis C who use drugs. Addict Behav (2017) 0.75
Post-treatment drinking among HIV patients: Relationship to pre-treatment marijuana and cocaine use. Drug Alcohol Depend (2015) 0.75
Phosphatidylethanol (PEth) as a Biomarker of Alcohol Consumption in HIV-Infected Young Russian Women: Comparison to Self-Report Assessments of Alcohol Use. AIDS Behav (2017) 0.75
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA (2006) 13.15
Brief interventions for alcohol problems: a meta-analytic review of controlled investigations in treatment-seeking and non-treatment-seeking populations. Addiction (2002) 9.47
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
HIV prevalence estimates--United States, 2006. MMWR Morb Mortal Wkly Rep (2008) 7.76
The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA (2000) 7.65
Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis (2001) 5.27
Host factors and the pathogenesis of HIV-induced disease. Nature (1996) 4.96
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology (1989) 2.53
Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol (2005) 2.27
Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology (2002) 2.18
Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology (1991) 2.06
Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol (2005) 1.92
Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol (1998) 1.91
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis (2002) 1.87
The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology (2001) 1.87
Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med (2008) 1.74
HIV treatment in drug abusers: impact of alcohol use. Addict Biol (2003) 1.72
Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol (2004) 1.69
Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry (2003) 1.67
HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem (2001) 1.53
Modification of the mitochondrial proteome in response to the stress of ethanol-dependent hepatotoxicity. J Biol Chem (2004) 1.51
Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci (2007) 1.49
Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol (2003) 1.30
Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther (2007) 1.26
Mitochondrial glutathione depletion in alcoholic liver disease. Alcohol (1994) 1.20
Pathogenesis of alcohol-induced accumulation of protein in the liver. J Clin Invest (1977) 1.13
Effects of chronic ethanol administration on rat liver proteasome activities: relationship with oxidative stress. Hepatology (1999) 1.07
How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem (1999) 1.07
Laureate ESCI award for excellence in clinical science 1999. Cytokines and the human immunodeficiency virus: from bench to bedside. European Society for Clinical Investigation. Eur J Clin Invest (1999) 1.05
Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS (2006) 1.05
Potentiation by chronic ethanol treatment of the mitochondrial permeability transition. Biochem Biophys Res Commun (1999) 1.02
Increase in the non-HIV-related deaths among AIDS cases in the HAART era. Curr HIV Res (2008) 0.99
Chronic ethanol feeding affects proteasome-interacting proteins. Proteomics (2009) 0.98
The human 26S proteasome is a target of antiretroviral agents. AIDS (2002) 0.98
Inhibition of proteasome function leads to NF-kappaB-independent IL-8 expression in human hepatocytes. Hepatology (2003) 0.98
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology (2004) 0.98
Implication of altered proteasome function in alcoholic liver injury. World J Gastroenterol (2007) 0.95
Role of apoptosis in alcoholic liver injury. Alcohol Clin Exp Res (2003) 0.94
Hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infections in alcoholics. Front Biosci (2002) 0.94
The ubiquitin-proteasome 26s pathway in liver cell protein turnover: effect of ethanol and drugs. Alcohol Clin Exp Res (2001) 0.91
The role of tumour necrosis factor-alpha in acquired immunodeficiency syndrome. J Intern Med (1990) 0.91
The ubiquitin-proteasome system and its role in ethanol-induced disorders. Addict Biol (2002) 0.88
Serum ubiquitin levels in patients with alcoholic liver disease. Alcohol Clin Exp Res (1999) 0.85
Implication of cytokines: Roles of tumor necrosis factor-alpha in liver injury. Hepatol Res (2008) 0.79
Ultrastructural identification and clinical significance of light microscopic giant mitochondria in alcoholic liver injuries. Gastroenterol Jpn (1989) 0.79
Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis (2011) 5.42
Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology (2003) 3.51
SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis (2008) 2.56
Pro-oxidant and cytotoxic effects of circulating heme. Blood (2002) 2.45
Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest (2009) 2.34
Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol (2008) 2.16
A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med (2007) 2.08
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology (2007) 1.79
Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res (2008) 1.78
Nanomaterial cytotoxicity is composition, size, and cell type dependent. Part Fibre Toxicol (2010) 1.75
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65
Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem (2007) 1.63
Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol (2008) 1.63
Heme, heme oxygenase, and ferritin: how the vascular endothelium survives (and dies) in an iron-rich environment. Antioxid Redox Signal (2007) 1.55
Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2008) 1.54
Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr (2007) 1.49
Zinc supplementation reverses alcohol-induced steatosis in mice through reactivating hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor-alpha. Hepatology (2009) 1.48
Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One (2013) 1.48
Polychlorinated biphenyls, lead, and mercury are associated with liver disease in American adults: NHANES 2003-2004. Environ Health Perspect (2010) 1.48
Zinc supplementation prevents alcoholic liver injury in mice through attenuation of oxidative stress. Am J Pathol (2005) 1.47
Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler Thromb Vasc Biol (2010) 1.44
Fructose takes a toll. Hepatology (2009) 1.44
Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem (2005) 1.41
A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF-alpha production. Am J Pathol (2003) 1.41
Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med (2009) 1.40
Chronic alcohol exposure stimulates adipose tissue lipolysis in mice: role of reverse triglyceride transport in the pathogenesis of alcoholic steatosis. Am J Pathol (2012) 1.37
Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol (2003) 1.36
Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur J Biochem (2003) 1.35
Intralysosomal iron: a major determinant of oxidant-induced cell death. Free Radic Biol Med (2003) 1.33
Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr (2004) 1.33
Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J Exp Med (2007) 1.32
Prevention of oxidant-induced cell death by lysosomotropic iron chelators. Free Radic Biol Med (2003) 1.31
Chronic ethanol-mediated decrease in cAMP primes macrophages to enhanced LPS-inducible NF-kappaB activity and TNF expression: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol (2006) 1.26
Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. JPEN J Parenter Enteral Nutr (2011) 1.23
Neuroprotection in cerebral ischemia by neutralization of 3-aminopropanal. Proc Natl Acad Sci U S A (2002) 1.23
The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol (2010) 1.23
Zinc and liver disease. Nutr Clin Pract (2012) 1.22
Decreased prevalence of nonalcoholic fatty liver disease in black obese children. J Pediatr Gastroenterol Nutr (2005) 1.22
Albumin therapy in clinical practice. Nutr Clin Pract (2005) 1.21
Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract (2008) 1.20
Inhibition of adiponectin production by homocysteine: a potential mechanism for alcoholic liver disease. Hepatology (2008) 1.20
Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr (2005) 1.19
Mechanisms and cell signaling in alcoholic liver disease. Biol Chem (2010) 1.19
Diverse antioxidants protect against acetaminophen hepatotoxicity. J Biochem Mol Toxicol (2004) 1.18
Oxygen tolerance and coupling of mitochondrial electron transport. J Biol Chem (2004) 1.17
Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database. Clin Ther (2012) 1.17
Aging of cardiac myocytes in culture: oxidative stress, lipofuscin accumulation, and mitochondrial turnover. Ann N Y Acad Sci (2004) 1.17
The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease. Alcohol Clin Exp Res (2011) 1.17
Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J Immunol (2013) 1.15
Prevention of alterations in intestinal permeability is involved in zinc inhibition of acute ethanol-induced liver damage in mice. J Pharmacol Exp Ther (2003) 1.14
Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. Am J Pathol (2011) 1.14
Mitochondrial recycling and aging of cardiac myocytes: the role of autophagocytosis. Exp Gerontol (2003) 1.13
Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am J Physiol Gastrointest Liver Physiol (2007) 1.12
Glutathione-enhancing agents protect against steatohepatitis in a dietary model. J Biochem Mol Toxicol (2006) 1.11
Treatment of alcoholic liver disease. Dig Dis (2005) 1.10
Abrogation of nuclear factor-kappaB activation is involved in zinc inhibition of lipopolysaccharide-induced tumor necrosis factor-alpha production and liver injury. Am J Pathol (2004) 1.10
Good fat/bad fat. Hepatology (2007) 1.10
Pancreatic response to endotoxin after chronic alcohol exposure: switch from apoptosis to necrosis? Am J Physiol Gastrointest Liver Physiol (2005) 1.10
Proteomic analysis of differentially expressed Chlamydia pneumoniae genes during persistent infection of HEp-2 cells. Infect Immun (2002) 1.10
Mitochondrial metabolism underlies hyperoxic cell damage. Free Radic Biol Med (2004) 1.07
Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol (2008) 1.06
PAI-1 plays a protective role in CCl4-induced hepatic fibrosis in mice: role of hepatocyte division. Am J Physiol Gastrointest Liver Physiol (2010) 1.06
S-adenosylhomocysteine sensitizes to TNF-alpha hepatotoxicity in mice and liver cells: a possible etiological factor in alcoholic liver disease. Hepatology (2004) 1.06
Treatment of alcoholic liver disease. Therap Adv Gastroenterol (2011) 1.06
Metabolomic analysis of the effects of polychlorinated biphenyls in nonalcoholic fatty liver disease. J Proteome Res (2012) 1.06
Heme, heme oxygenase and ferritin in vascular endothelial cell injury. Mol Nutr Food Res (2005) 1.05
Histamine release and fibrinogen adsorption mediate acute inflammatory responses to biomaterial implants in humans. J Transl Med (2007) 1.05
Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. Int J Infect Dis (2012) 1.05
The role of lysosomes in iron metabolism and recycling. Int J Biochem Cell Biol (2011) 1.04
Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Panton-Valentine leukocidin gene. Clin Infect Dis (2011) 1.04
Mitochondrial DNA damage in iron overload. J Biol Chem (2008) 1.04
Global changes in the epidemiology of community-acquired pneumonia. Semin Respir Crit Care Med (2012) 1.03
Analysis of pathogen and host factors related to clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus. J Clin Microbiol (2012) 1.03
Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J Nutr Biochem (2010) 1.03
Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone improves lipid homeostasis at the adipose tissue-liver axis in ethanol-fed mice. Am J Physiol Gastrointest Liver Physiol (2011) 1.03
Polychlorinated biphenyl 153 is a diet-dependent obesogen that worsens nonalcoholic fatty liver disease in male C57BL6/J mice. J Nutr Biochem (2013) 1.02
New role of resistin in lipopolysaccharide-induced liver damage in mice. J Pharmacol Exp Ther (2008) 1.02
Toxicant-associated steatohepatitis in vinyl chloride workers. Hepatology (2010) 1.02
Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest (2003) 1.02
Toxicant-associated steatohepatitis. Toxicol Pathol (2012) 1.01
Generation of oxidants by hypoxic human pulmonary and coronary smooth-muscle cells. Chest (2008) 1.01
Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD. J Clin Endocrinol Metab (2012) 1.01
Angiotensin II plays a critical role in alcohol-induced cardiac nitrative damage, cell death, remodeling, and cardiomyopathy in a protein kinase C/nicotinamide adenine dinucleotide phosphate oxidase-dependent manner. J Am Coll Cardiol (2012) 1.00
Evaluation of the knowledge-sharing social network of hospital-based infection preventionists in Kentucky. Am J Infect Control (2011) 0.99
Advances in alcoholic liver disease. Curr Gastroenterol Rep (2011) 0.98
Inhibition of proteasome function leads to NF-kappaB-independent IL-8 expression in human hepatocytes. Hepatology (2003) 0.98
Zinc supplementation inhibits hepatic apoptosis in mice subjected to a long-term ethanol exposure. Exp Biol Med (Maywood) (2008) 0.98
Alcohol-induced S-adenosylhomocysteine accumulation in the liver sensitizes to TNF hepatotoxicity: possible involvement of mitochondrial S-adenosylmethionine transport. Biochem Pharmacol (2007) 0.98
Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model. Neoplasia (2007) 0.97
Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. Alcohol Clin Exp Res (2005) 0.97
Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med (2013) 0.96
Clinical implications of oxidative stress and antioxidant therapy. Curr Gastroenterol Rep (2005) 0.96